FEATURED ARTICLE

 

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal stud

PR Newswire  2018-01-16 23:17:00

SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on a proprietary Photoimmunotherapy (PIT) platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Full Story »

Comments

No Comments
Your name: *
Email:
Comment: *
 
Share
submit to reddit
Save On Airport Parking